7679 The Role of Thyrotoxicosis in Determining Clinical Outcomes for Hospitalized Patients with Dilated Cardiomyopathy: A Propensity Match National Cohort

Abstract Disclosure: R. Mukhtar: None. H. Younas: None. A. Taha: None. D. Virlan: None. A. Ceban: None. A. Racovita: None. J. Patel: None. Background: Thyrotoxicosis, a condition associated with high morbidity and mortality, has been notably linked to adverse clinical outcomes in patients with cardiovascular diseases. This study aims to comprehensively analyze the clinical impact of thyrotoxicosis on in-hospital outcomes in patients hospitalized with DCM. Methods: Based on 2020 National In-patient Sample Database, DCM patients were categorized into two groups depending on whether thyrotoxicosis was present or absent at the time of admission. To evaluate the impact of thyrotoxicosis on clinical outcomes, comparative analyses were conducted using propensity score matching and multivariable regression analysis. All statistical analyses were performed using STAT v 17. Results: Among 545,390 hospitalizations for DCM, 2,900 (0.5%) patients were presented with thyrotoxicosis. Propensity score matching revealed that DCM patients with thyrotoxicosis had higher heart failure rates (7.87% vs. 5.62%, aOR: 1.39, 95% CI: 1.04-1.86, p-value: 0.03). There was no statistically significant difference in in-patient mortality (2.60% vs. 3.65%, aOR: 0.81, 95% CI 0.58-1.13, p-value: 0.21), conduction disorders (3.26% vs. 2.70%, aOR: 1.38, 95% CI: 0.89-2.13, p-value: 0.15), acute coronary artery syndrome (0.62% vs. 0.86%, aOR: 0.94, 95% CI: 0.54-1.64, p-value: 0.82), acute kidney injury (18.57% vs. 18.59%, aOR 0.99, 95% CI: 0.77-1.17, p-value: 0.62), and acute stroke (0.29% vs. 0.30%, aOR: 0.60, 95% CI: 0.15-2.44, p-value: 0.48) between DCM patients with and without thyrotoxicosis. Thyrotoxicosis was associated with increased length of stay [5 days (IQR: 6) vs. 4 days (IQR: 7)] and total charge [$54,256 (IQR: 82,126) vs. $47,942 (IQR: 75,003)] in patients admitted with DCM. Conclusion: This research indicates that DCM patients co-presenting with thyrotoxicosis have an increased risk of heart failure and resource utilization during hospitalization. There were no significant effects observed in conduction disorders, in-patient mortality, acute coronary, kidney, or stroke outcomes among DCM patients hospitalized with or without thyrotoxicosis. Future prospective studies are warranted to enhance our understanding of clinical outcomes associated with thyrotoxicosis in patients hospitalized with DCM. Presentation: 6/3/2024